Integrase Inhibitors: all 515 studies that test it
Page 6 of 6. Open to participants first (36), then studies with results posted, then the rest; newest registration first within each.
- Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive PatientsCompletedNCT00677300Phase 4
- Raltegravir as Early Therapy in African-Americans Living With HIV StudyCompletedNCT00667433Phase 1
- The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)CompletedNCT00665717Phase 1
- Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)CompletedNCT00660972Phase 1
- A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744CompletedNCT00659191Phase 1
- GSK1349572 Repeat Dose Escalation and Relative Bioavailability StudyCompletedNCT00631592Phase 1
- Pharmacokinetic Study on Raltegravir and LamotrigineCompletedNCT00618241Phase 1
- Raltegravir Kaletra PharmacokineticsCompletedNCT00564772Phase 4
- Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 RecoveryTerminatedNCT00562510Phase 3
- GSK1349572 First Time in Human StudyCompletedNCT00555035Phase 1
- Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral SuppressionCompletedNCT00554398Phase 3
- Switching From PI to RALtegravir in HIV Stable PatientsCompletedNCT00528892Phase 3
- Integrase Inhibitor (MK-0518) Viral DecayCompletedNCT00520897Phase 2
- DDI HV (ATV - Merck)CompletedNCT00518297Phase 1
- Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.CompletedNCT00298350Phase 2